Figure 3
From: Scope of nanotechnology in ovarian cancer therapeutics
A schematic representation of the strategy to target cancer cells using nanoparticles and immunoconjugated nanoparticles. Passive targeting occurs through drug loaded nanoparticles and active targeting is achieved with antibody conjugated nanoparticles.